Literature DB >> 33731681

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.

Patrick K Reville1, Hagop M Kantarjian2, Farhad Ravandi2, Elias Jabbour2, Courtney D DiNardo2, Naval Daver2, Naveen Pemmaraju2, Maro Ohanian2, Yesid Alvarado2, Lianchun Xiao3, Gheath Alatrash4, Sanam Loghavi5, Caitlin R Rausch6, Gautam Borthakur2, Marina Konopleva2, Jorge Cortes7, Tapan M Kadia8.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33731681      PMCID: PMC7969746          DOI: 10.1038/s41408-021-00453-z

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN: 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  11 in total

1.  Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

Authors:  Andrew H Wei; Hartmut Döhner; Christopher Pocock; Pau Montesinos; Boris Afanasyev; Hervé Dombret; Farhad Ravandi; Hamid Sayar; Jun-Ho Jang; Kimmo Porkka; Dominik Selleslag; Irwindeep Sandhu; Mehmet Turgut; Valentina Giai; Yishai Ofran; Merih Kizil Çakar; Aida Botelho de Sousa; Justyna Rybka; Chiara Frairia; Lorenza Borin; Germana Beltrami; Jaroslav Čermák; Gert J Ossenkoppele; Ignazia La Torre; Barry Skikne; Keshava Kumar; Qian Dong; C L Beach; Gail J Roboz
Journal:  N Engl J Med       Date:  2020-12-24       Impact factor: 91.245

Review 2.  Treatment of relapsed/refractory acute myeloid leukaemia in adults.

Authors:  Armin Rashidi; Daniel J Weisdorf; Nelli Bejanyan
Journal:  Br J Haematol       Date:  2018-01-09       Impact factor: 6.998

3.  Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.

Authors:  Padmanee Sharma; Hagop Kantarjian; Naval Daver; Guillermo Garcia-Manero; Sreyashi Basu; Prajwal C Boddu; Mansour Alfayez; Jorge E Cortes; Marina Konopleva; Farhad Ravandi-Kashani; Elias Jabbour; Tapan Kadia; Graciela M Nogueras-Gonzalez; Jing Ning; Naveen Pemmaraju; Courtney D DiNardo; Michael Andreeff; Sherry A Pierce; Tauna Gordon; Steven M Kornblau; Wilmer Flores; Zainab Alhamal; Carlos Bueso-Ramos; Jeffrey L Jorgensen; Keyur P Patel; Jorge Blando; James P Allison
Journal:  Cancer Discov       Date:  2018-11-08       Impact factor: 39.397

Review 4.  Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.

Authors:  Armin Rashidi; Roland B Walter; Martin S Tallman; Frederick R Appelbaum; John F DiPersio
Journal:  Blood       Date:  2016-06-27       Impact factor: 22.113

Review 5.  How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?

Authors:  Jie Xu; Jeffrey L Jorgensen; Sa A Wang
Journal:  Clin Lab Med       Date:  2017-09-28       Impact factor: 1.935

6.  Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.

Authors:  Gerwin Huls; Dana A Chitu; Violaine Havelange; Mojca Jongen-Lavrencic; Arjan A van de Loosdrecht; Bart J Biemond; Harm Sinnige; Beata Hodossy; Carlos Graux; Rien van Marwijk Kooy; Okke de Weerdt; Dimitri Breems; Saskia Klein; Jürgen Kuball; Dries Deeren; Wim Terpstra; Marie-Christiane Vekemans; Gert J Ossenkoppele; Edo Vellenga; Bob Löwenberg
Journal:  Blood       Date:  2019-01-10       Impact factor: 22.113

7.  Graft-versus-leukemia reactions after bone marrow transplantation.

Authors:  M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

8.  HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.

Authors:  Loren Gragert; Mary Eapen; Eric Williams; John Freeman; Stephen Spellman; Robert Baitty; Robert Hartzman; J Douglas Rizzo; Mary Horowitz; Dennis Confer; Martin Maiers
Journal:  N Engl J Med       Date:  2014-07-24       Impact factor: 91.245

Review 9.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Authors:  John Koreth; Richard Schlenk; Kenneth J Kopecky; Sumihisa Honda; Jorge Sierra; Benjamin J Djulbegovic; Martha Wadleigh; Daniel J DeAngelo; Richard M Stone; Hisashi Sakamaki; Frederick R Appelbaum; Hartmut Döhner; Joseph H Antin; Robert J Soiffer; Corey Cutler
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

Review 10.  Acute myeloid leukemia in the older adults.

Authors:  Antonio M Almeida; Fernando Ramos
Journal:  Leuk Res Rep       Date:  2016-06-16
View more
  3 in total

1.  Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.

Authors:  Fabiana Perna; Manuel R Espinoza-Gutarra; Giuseppe Bombaci; Sherif S Farag; Jennifer E Schwartz
Journal:  Cancer Treat Res       Date:  2022

Review 2.  Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia.

Authors:  Steven A Manobianco; Tara Rakiewicz; Lindsay Wilde; Neil D Palmisiano
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

Review 3.  Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Yasmin Abaza; Amer M Zeidan
Journal:  Cells       Date:  2022-07-20       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.